VanEck Associates
EXAS

VanEck Associates’s Exact Sciences EXAS Stock Holding History

VanEck Associates’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.19M Sell
20,917
-88,209
-81% -$9.08M ﹤0.01% 970
2025
Q4 		$11.1M Sell
109,126
-5,813
-5% -$467K 0.01% 533
2025
Q3 		$6.29M Sell
114,939
-5,860
-5% -$293K 0.01% 682
2025
Q2 		$6.42M Sell
120,799
-6,792
-5% -$345K 0.01% 631
2025
Q1 		$5.52M Buy
127,591
+4,749
+4% +$240K 0.01% 673
2024
Q4 		$6.9M Sell
122,842
-13,023
-10% -$810K 0.01% 581
2024
Q3 		$9.55M Sell
135,865
-17,484
-11% -$987K 0.01% 457
2024
Q2 		$6.48M Buy
153,349
+7,785
+5% +$428K 0.01% 512
2024
Q1 		$10.1M Buy
145,564
+5,174
+4% +$327K 0.02% 400
2023
Q4 		$10.4M Sell
140,390
-9,078
-6% -$595K 0.02% 361
2023
Q3 		$10.2M Sell
149,468
-16,345
-10% -$1.39M 0.02% 341
2023
Q2 		$15.6M Sell
165,813
-1,969
-1% -$154K 0.03% 286
2023
Q1 		$11.4M Sell
167,782
-30,116
-15% -$1.94M 0.03% 325
2022
Q4 		$9.8M Buy
197,898
+68,538
+53% +$2.8M 0.03% 340
2022
Q3 		$4.2M Sell
129,360
-47,410
-27% -$1.95M 0.01% 470
2022
Q2 		$6.96M Sell
176,770
-5,638
-3% -$301K 0.02% 387
2022
Q1 		$12.8M Buy
182,408
+116
+0.1% +$8.48K 0.03% 324
2021
Q4 		$14.2M Sell
182,292
-13,301
-7% -$1.17M 0.03% 306
2021
Q3 		$18.7M Sell
195,593
-15,920
-8% -$1.68M 0.05% 252
2021
Q2 		$26.3M Buy
211,513
+42,417
+25% +$5.06M 0.06% 225
2021
Q1 		$22.3M Buy
169,096
+5,379
+3% +$736K 0.06% 213
2020
Q4 		$21.7M Sell
163,717
-21,095
-11% -$2.55M 0.06% 199
2020
Q3 		$18.8M Sell
184,812
-31,108
-14% -$2.69M 0.06% 190
2020
Q2 		$18.8M Buy
215,920
+30,677
+17% +$2.45M 0.07% 183
2020
Q1 		$10.7M Sell
185,243
-4,214
-2% -$342K 0.05% 203
2019
Q4 		$17.5M Buy
189,457
+52,679
+39% +$4.63M 0.07% 191
2019
Q3 		$12.4M Sell
136,778
-3,950
-3% -$450K 0.06% 200
2019
Q2 		$16.6M Sell
140,728
-72,333
-34% -$7.29M 0.08% 180
2019
Q1 		$18.5M Sell
213,061
-38,286
-15% -$3.26M 0.09% 169
2018
Q4 		$15.9M Sell
251,347
-7,454
-3% -$512K 0.08% 187
2018
Q3 		$20.4M Buy
+258,801
New +$16.9M 0.1% 178

Other funds holding EXAS

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.16B AUM 28.78% 1-Year Est. Return
PWMAG
Pinnacle Wealth Management Advisory Group Red Bank, New Jersey $1.68B AUM 31.18% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return
BC
Broadwater Capital Boston, Massachusetts $138M AUM 28.86% 1-Year Est. Return

VanEck Associates's EXAS Position: Q1 2026 in Review

VanEck Associates reduced its Exact Sciences (EXAS) stake by 81% in Q1 2026, selling an estimated $9.08M and leaving 20,917 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #970.

VanEck Associates first reported a position in EXAS in Q3 2018 and has held it in 31 quarters since. The position peaked at $26.3M in Q2 2021. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • VanEck Associates held 20,917 shares of Exact Sciences worth $2.19M as of Q1 2026.
  • VanEck Associates sold 88,209 Exact Sciences shares in Q1 2026, an estimated $9.08M.
  • Exact Sciences made up ﹤0.01% of VanEck Associates's portfolio in Q1 2026, its #970 holding.
  • VanEck Associates first reported a position in Exact Sciences in Q3 2018 and has held it in 31 quarters since.
  • VanEck Associates's Exact Sciences position peaked at $26.3M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on VanEck Associates's 13F filing for Q1 2026, filed 15 May 2026.